Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O75165

UPID:
DJC13_HUMAN

ALTERNATIVE NAMES:
Required for receptor-mediated endocytosis 8

ALTERNATIVE UPACC:
O75165; Q3L0T1; Q6PI82; Q6UJ77; Q6ZSW1; Q6ZUT5; Q86XG3; Q96DC1; Q9BWK9

BACKGROUND:
The protein DnaJ homolog subfamily C member 13, alternatively named Required for receptor-mediated endocytosis 8, is integral to early endosome processes. It facilitates the early to recycling endosome transport crucial for transferrin recycling and early to late endosome transport for EGF and EGFR degradation. Its role in endosomal membrane tubulation and SNX1 dynamics regulation, through its interaction with WASHC2, highlights its importance in cellular trafficking.

THERAPEUTIC SIGNIFICANCE:
The association of DNAJC13 with Parkinson disease, characterized by dopaminergic neuron loss and Lewy bodies, underscores its potential in disease pathogenesis. Exploring DnaJ homolog subfamily C member 13's function offers a promising avenue for developing novel therapeutic interventions for Parkinson's disease.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.